Revenue
2021
2022
2023
2024
2025
Pentixapharm Holding AG (PTP)
Price€1.85Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €90,000 | €120,000 | €20,000 | €30,000 | €60,000 |
| Gross profit | −€6.7M | −€3.6M | −€30,000 | €30,000 | €60,000 |
| Gross margin | −7,444.44% | −3,000.00% | −150.00% | 100.00% | 100.00% |
| Research & development | €205,000 | N/A | €8.3M | €4.3M | €2.9M |
| Operating expenses | €13.2M | €13.8M | €6.1M | €2.2M | €1.7M |
| Operating income | −€19.9M | −€17.4M | −€6.2M | −€2.2M | −€1.6M |
| Operating margin | −22,066.67% | −14,491.67% | −30,800.00% | −7,266.67% | −2,733.33% |
| EBITDA | −€15.8M | €2.5M | −€5.9M | −€665,000 | N/A |
| EBITDA margin | −17,536.67% | 2,122.50% | −29,420.00% | −2,216.67% | N/A |
| Net income | −€16.5M | −€12.8M | −€7.6M | −€2.0M | −€2.5M |
| Net profit margin | −18,344.44% | −10,700.00% | −38,200.00% | −6,533.33% | −4,150.00% |
| Basic EPSper basic share | -€0.67 | -€0.52 | -€0.31 | -€0.08 | -€0.10 |
| Diluted EPSper diluted share | -€0.67 | -€0.52 | -€0.31 | -€0.08 | -€0.10 |
Owners
Reported major voting-rights holders
3.15%of voting rights
Morgan StanleyNotified Jul 31, 2026
View holders
| Holder | Voting rights |
|---|---|
| 3.15%Jul 31, 2026 · 1.13M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Issuer voting-rights announcement via EQS ↗Updated Oct 21, 2026